# EDGAR Filing Document

**Accession Number:** 0001878313
**File Stem:** 0001493152-26-024325
**Filing Date:** 2026-5
**Character Count:** 4710
**Document Hash:** 7860402d59656046269fda888980ca09
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-024325.hdr.sgml**: 20260519

**ACCESSION NUMBER**: 0001493152-26-024325

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260519

**DATE AS OF CHANGE**: 20260519

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAIA Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001878313
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41455
- **FILM NUMBER:** 26995792

**BUSINESS ADDRESS:**
- **STREET 1:** 444 WEST LAKE STREET, SUITE 1700
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606
- **BUSINESS PHONE:** 312-416-8592

**MAIL ADDRESS:**
- **STREET 1:** 444 WEST LAKE STREET, SUITE 1700
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of<br> the Securities Exchange Act of 1934

(Amendment No. 1)

Filed by the Registrant ☒

Filed by a Party other than the Registrant

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

**<u>MAIA Biotechnology, Inc.</u>**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

**(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)**

**Payment of Filing Fee (Check all boxes that apply):**

☒ No fee required

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

**MAIA Biotechnology, Inc.**

**Amendment and Supplement to the Proxy Statement**

**For the Annual Meeting of Stockholders**

**To be Held on May 21, 2026**

**EXPLANATORY NOTE**

On April 7, 2026, MAIA Biotechnology, Inc. ("MAIA" or the "Company") filed its definitive proxy statement (the "Proxy Statement") with the Securities and Exchange Commission ("SEC") for its annual meeting of shareholders to be held on June 9, 2025 (the "Annual Meeting").

The Company is amending and supplementing the Proxy Statement with the information provided in this amendment and supplement to the Proxy Statement (the "Amendment and Supplement") to update the disclosure related to compensation received in the years ended December 31, 2025 and 2024 by the brother of the Company's Chief Executive Officer in the section entitled "CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS" in the Proxy Statement

**Any proxies submitted by stockholders before the date of this Amendment and Supplement will be voted as instructed on those proxies, unless a stockholder changes his or her vote by submitting a later dated proxy. Stockholders should follow the instructions described in the Proxy Statement regarding how to submit proxies or vote at the Annual Meeting.**

**THIS AMENDMENT AND SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.**

*This supplemental information should be read in conjunction with the Proxy Statement, which should be read in its entirety. Section references in the below disclosures are to sections in the Proxy Statement, and defined terms used but not defined herein have the meanings set forth in the Proxy Statement. To the extent the following information differs from or conflicts with the information contained in the Proxy Statement, the information set forth below shall be deemed to supersede the respective information in the Proxy Statement.*

**Amendments and Supplemental Disclosure**

**<u>Proxy Statement</u>**

**The section entitled "CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS" in the Proxy Statement is amended to include the disclosure below related compensation received by the brother of the Chief Executive Officer in the years ended December 31, 2025 and 2024 as follows:**

"We paid R<u>a</u>du Vitoc, brother of our Chief Executive Officer Vlad Vitoc total compensation of $286,321 in the year ended December 31, 2025, consisting of $213,000 in cash and 39,000 options with a value of $73,321. In the year ended December 31, 2024, we paid Radu Vitoc total compensation of $242,102, consisting of $172,500 in cash and 50,000 options with a value of $69,602. Mr. Vitoc's compensation in each of 2025 and 2024 was in line with industry standards."

<u>May 19, 2026</u>